OncoSil MEDICAL

CEO AGM Presentation

19 October 2021

Targeted Approach • Positive Impact



OncoSil Medical's targeted approach will deliver a positive impact in the treatment of pancreatic cancer, aimed at extending the length and quality of life for patients

OncoSil™ Device

Overview

OncoSil™ is intended for the treatment of **locally advanced unresectable pancreatic cancer,** in combination with gemcitabine-based chemotherapy.

OncoSil™ is a **single-use** brachytherapy device comprised of microparticles and a diluent.

OncoSil™ is **implanted directly** into a pancreatic tumour via injection under **endoscopic ultrasound** guidance.

98% of all radiation is delivered within **81** days of injection...

...causing direct damage to cancer cell DNA, and ultimately shrinking tumour masses when the cells die.

Management Team with a Depth of Experience and Expertise

Nigel Lange
Managing Director & CEO

30+ years experience in medical device industry

Served as Group COO and Interim Group CEO of Sirtex Medical

Dr Ralph Peters
Chief Medical Officer

30+ years experience in diagnostic and interventional radiology

EMEA Medical Director of Sirtex Medical from 2005 - 2020

David Turner
Head of Medical Affairs

40+ years experience in pharmaceutical, medical device and health technology industries

Henk Tissing
Director of Clinical Development

25+ years industry experience in oncology with pharmaceuticals and medical devices.

Clinical development roles at Sirtex Medical, BTG, A-Z & Sanofi Aventis

Olaf Michaelsen
Director AREA[1]

25+ years experience in implantable medical devices

Previous commercial roles at Sirtex Medical, Medtronic and LifeCell

Karl Pechmann
CFO

Former CFO of Kyckr, and has held several finance roles for listed and multi-national organisations

Nicole Wilson
VP, Regulatory Affairs and Quality

15+ years regulatory medical device experience

David James
Global Head, Manufacturing & Operations

25+ years of pharmaceutical manufacturing operations experience

1: Access, Reimbursement, Economics and Assessment

Achievements so far

- **PanCO Study completed**
- **CE Marking obtained**
- **Breakthrough device designation achieved** in US, EU, UK, Singapore
- **Enabled HDE pathway for bile duct cancer in US enabled** – application submitted to FDA



Current Market Approvals
Europe (CE Mark)
United Kingdom
Switzerland
Singapore
Malaysia
Hong Kong
New Zealand
Turkey
Israel

FDA: Food and Drug Administration
HDE: Humanitarian Device Exemption
* Distal cholangiocarcinoma (DCC or bile duct cancer)

Go-To Market Execution Progress

Preparation of OSPREY Sites	Ethics applications in progress in over 25 hospitals in the following markets: UK, Germany, France, Spain, Italy, Portugal, Turkey and Israel.	Training to be completed by end of November 2021	
Market Access and reimbursement	Preparation of health insurance access and hospital reimbursement application for Submission through German Hospitals	Exploration of health insurance market access avenues in target markets	Initiated first steps in developing a global value dossier and budget impact analysis for the requirements of health insurances and health technology assessment agencies
Clinical Development Plan	Clinical development plan in progress to address regulatory as well as clinical outcome requirements from the scientific community		
Utilise the SAS Special Access Scheme	Treatment permissible under SAS scheme in Australia as long as we do not promote the therapy		
HDE Application: Distal cholangiocarcinoma	Humanitarian Device Exemption (HDE) application submitted with the US FDA for its OncoSil™ device in the treatment of distal cholangiocarcinoma	Dataset updated to include final safety and efficacy data from the PanCO and OncoPaC-1 trials as per request from the FDA	The data set submitted October after delays due to COVID restrictions at sites. Awaiting response and queries from FDA

FDA: Food and Drug Administration
HDE: Humanitarian Device Exemption

HDE Application for Distal Cholangiocarcinoma

Where are we now?



FDA: Food and Drug Administration
* Distal cholangiocarcinoma (DCC), also known as bile-duct cancer

Commercial Opportunity Expansion

Current Position:

- **Approved in:**
  - Europe (CE Mark)
  - Switzerland
  - Singapore
  - Malaysia
  - Hong Kong
  - New Zealand
  - United Kingdom
  - Israel
  - Turkey
- **Private payer markets and limited hospital public funding**
- **In combination with gemcitabine-based chemotherapy**

Expansion opportunity:

- **Commercialise OncoSil™ device in the USA under FDA HDE approval**
- **Expand Label to include FOLFIRINOX chemo**
- **Alternative device delivery methods**
- **Secure US FDA PMA approval in LAPC**
- **Possible indication expansion**
- **Generate clinical evidence to access public payer markets globally: Secure reimbursement**



FDA: Food and Drug Administration
HCPCS: Healthcare Common Procedure Coding System
HDE: Humanitarian Device Exemption

LAPC: Locally Advanced Pancreatic Cancer
PMA: Pre-Market Approval

Disclaimer

This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (**OncoSil** or the **Company**) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website www.oncosil.com.au for further information.

Not an Offer for Securities

Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction. This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act.

Forward-Looking Statements

This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved. In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined herein. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

Disclaimer

This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents.

The information contained in this presentation is current as at 19 October 2021.

Nigel Lange
CEO & Managing Director

E: nigel.lange@oncosil.com

OncoSil Medical Ltd
www.oncosil.com

T: +49 160 9642 4981

Targeted Approach • Positive Impact